Predictive Oncology (NASDAQ: POAI) Subsidiary’s HSC Technology Optimization Solution Offers Unparalleled Results, Benefits
POAI subsidiary Soluble Biotech’s optimization solution shaves time and cost off of traditional options offered by competition Results garnered from company’s HSC optimization are unparalleled in field Soluble Biotech lands first major contract, signifying major company milestone Offering a proprietary automated High Throughput Self-Interaction Chromatography(TM) (“HSC”) Technology Platform, Predictive Oncology (NASDAQ: POAI) provides biomedical and pharmaceutical companies with superior options never before available. A knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, POAI, through its subsidiary Soluble Biotech, delivers a solution that reduces the cost, time and manpower needed to optimize therapeutic formulations. HSC…